On Monday, Eli Lilly And Co (NYSE:LLY) announced plans to boost its presence in the U.K., following a collaboration with the U.K. government that was revealed at the International Investment Summit.
The global pharmaceutical giant is set to invest in a new Gateway Lab in the U.K., building on the country's leading life sciences sector. This 279 million pounds ($294.41 million) investment will tackle significant health challenges and further solidify the U.K.'s reputation as a world leader in healthcare innovation.
The life sciences sector is already worth 108 billion pounds to the U.K. economy, and the partnership with Lilly demonstrates its ongoing value in advancing public health.
With the planned Gateway Lab marking the first such facility in Europe, the U.K. is positioning itself at the forefront ...
